Novo Nordisk A/S is a Danish multinational pharmaceutical company helping to defeat diabetes, rare bleeding disorders, growth hormone-related disorders, and obesity.

According to the law firm press release, the Complaint alleges that during the Class Period, Novo Nordisk reported materially false and misleading earnings and forecasts in that they were inflated through the collusive price fixing of the Company's insulin drugs. The Complaint also alleges that Novo Nordisk misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers.

A consolidated and amended Complaint was filed on August 4. Defendants filed a Motion to Dismiss the amended Complaint on October 3. On August 16, 2018, the Court issued an Order denying Defendants' Motion to Dismiss.

Plaintiffs filed a Motion for Class Certification on April 1, 2019. On January 31, 2020, the Court issued an Order granting the Class Certification motion.

On September 29, 2021, the parties notified the Court that they had reached a settlement in principle. On November 23, the parties entered into a Stipulation and Agreement of Settlement. The Court granted preliminary approval of the Settlement on March 8, 2022. On July 13, the Court granted final approval of the Settlement, including an award of Attorneys’ Fees and Expenses, and entered Final Judgment.

The Court issued an Order approving the Settlement's distribution on March 21, 2024.